Guardant Health, Inc. (GH)’s ctDNA Test Predicts Colon Cancer Recurrence Risk in Stage III Patients
Guardant Health, Inc.
Guardant Health Inc. (GH)
Market is closed
Sector: Services-Medical Laboratories
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 5,443,721 | $231,902,515 | -16% | 7.51% |
| 2. | 219,454,000 | $227,414,452 | 7.99% | ||
| 3. | Cadian Capital Eric Bannasch | 4,595,087 | $195,750,706 | -12% | 8.38% |
| 4. | Citadel Investment Group Ken Griffin | 3,596,913 | $153,228,494 | +143% | 0.03% |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 2,367,800 | $100,868,280 | +3% | 0.23% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.82 | 2,187 | $38,962.72 | 12,722 | 2024-03-18 | Filing | |
| $32.78 | 750 | $24,584.25 | 5,193 | 2023-06-09 | Filing | |
| $32.68 | 2,231 | $72,913.77 | 4,443 | 2023-06-09 | Filing | |
| $26.15 | 8,600 | $224,927.84 | 2,049,238 | 2023-03-15 | Filing | |
| $26.33 | 84,452 | $2,223,908.30 | 2,040,638 | 2023-03-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $51.40 | 27,932 | $1,435,836.08 | 1,971,830 | 2025-07-01 | Filing | |
| $50.67 | 72,068 | $3,651,793.66 | 1,999,762 | 2025-07-01 | Filing | |
| $49.47 | 3,213 | $158,947.11 | 7,190 | 2025-06-18 | Filing | |
| $49.47 | 26 | $1,286.22 | 18,154 | 2025-06-18 | Filing | |
| $48.38 | 6,672 | $322,818.72 | 9,851 | 2025-06-17 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 279,000 | $324,524 | 0.04% | |
| 2. | 134,000 | $121,188 | 0.02% |
News See All
Guardant Health, Inc. (GH) Expands Liquid Biopsy to Pinpoint Tumor Origins and Biomarkers
Guardant Health, Inc. (NASDAQ:GH) has introduced major upgrades to its Guardant360 Liquid biopsy test, significantly expanding its cancer biomarker detection and subtyping abilities.
Guardant Health (GH) introduces IHC Solid Tumor Testing to its Portfolio
On May 21, Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular profiling tests.
Guardant Health, Inc. (NASDAQ:GH) Q1 2025 Earnings Call Transcript
Operator: Hello, everybody and welcome to the Guardant Health Q1 2025 Earnings Call. My name is Elliot, and I will be your coordinator today.
Guardant Health (GH) Rose Following Several Positive News Reports
Aristotle Atlantic Partners, LLC, an investment advisor, released its “Core Equity Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here.
10 Best Performing Mid Cap Stocks to Buy According to Analysts
On February 7, Simeon Hyman, Global Investment Strategist at ProShares Advisors, appeared on CNBC to discuss the upcoming jobs report and its expected impact on the market.
Guardant Health, Inc. (NASDAQ:GH) Q4 2024 Earnings Call Transcript
Operator: Good afternoon. Thank you for attending today's Guardant Health Q4 2024 Earnings Call. My name is Tamia and I will be your moderator for today's call.
10 Best Performing Healthcare Stocks So Far in 2025
Despite the ongoing craze surrounding the GLP-1 obesity drugs, the healthcare sector was a lagger last year.
Why These 15 Stocks Are Skyrocketing in 2025
Stock gains always get people talking, and 2025 is no exception. Markets have moved higher for a while due to a shift toward tech innovation.
Billionaire Hedge Funds
